Doximity, Inc. (DOCS)

Federated Hermes Inc. reduced its position in Doximity, Inc. (NASDAQ: DOCS) by 32.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 186,986 shares of the company's stock after selling 89,985 shares during the period. Federated Hermes Inc. owned about 0.10% of Doximity worth $11,470,000 as

Baird Financial Group Inc. purchased a new stake in shares of Doximity, Inc. (NASDAQ: DOCS) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 67,474 shares of the company's stock, valued at approximately $4,139,000. Other institutional investors have also added to or reduced their stakes

Pre-Market Stock Futures: The futures are trading flat on Tuesday after we opened the week on the downside, with all major indices finishing the day lower. With the Federal Reserve meeting this week, investors are playing a wait-and-see game before bidding stocks higher to ensure there will indeed be a 25-basis-point cut. Wall Street will... Here Are Tuesday's Top Wall Street Analyst Research Calls: Agilent, Alibaba, Delta Air Lines, Intel, JD.com, Micron Technology, Reddit and More.

Doximity, Inc. (NASDAQ: DOCS - Get Free Report) shares reached a new 52-week low during trading on Saturday. The stock traded as low as $45.29 and last traded at $45.9260, with a volume of 6994938 shares traded. The stock had previously closed at $51.31. Analyst Upgrades and Downgrades DOCS has been the topic of a

Doximity's Q2 results show record engagement and accelerating adoption of AI workflow tools, signaling deeper physician reliance on the platform. Revenue quality is improving as pharma clients shift from one-off ad buys to longer-term integrated programs. Doximity has a strong Rule-of-50 profile with high margins and $890m cash but no debt.

Edgestream Partners L.P. raised its stake in Doximity, Inc. (NASDAQ: DOCS) by 92.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 80,114 shares of the company's stock after acquiring an additional 38,540 shares during the quarter. Edgestream Partners

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Creative Planning lowered its stake in shares of Doximity, Inc. (NASDAQ: DOCS) by 6.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,906 shares of the company's stock after selling 2,106 shares during the quarter. Creative Planning's holdings in

CVNA last traded at $313.25 a share after finding support at $285.02, which was double-bottom support dating back to June 2025.

Dr Martens PLC (LSE:DOCS) shares stomped almost 7% lower to 76p after the bootmaker reported first half results in line with market expectations, saying it expects to offset the full-year effect of US tariffs.  Revenue for the 26 weeks to 28 September came in at £322 million, down 0.8% versus a year ago, or up 0.8% on a constant currency basis.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.

Doximity, Inc. ( DOCS ) Q2 2026 Earnings Call November 6, 2025 5:00 PM EST Company Participants Perry Gold - Head of Investor Relations Jeffrey Tangney - Co-Founder, CEO & Chairperson Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James & Associates, Inc., Research Division Michael Cherny - Leerink Partners LLC, Research Division Allen Lutz - BofA Securities, Research Division Ryan Daniels - William Blair & Company L.L.C., Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Ryan MacDonald - Needham & Company, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Craig Hettenbach - Morgan Stanley, Research Division Derek Gross - Piper Sandler & Co., Research Division Brian Tanquilut - Jefferies LLC, Research Division Stanislav Berenshteyn - Wells Fargo Securities, LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division David Roman - Goldman Sachs Group, Inc., Research Division Eric Percher - Nephron Research LLC Jenny Shen - BTIG, LLC, Research Division Jenny Cao - Truist Securities, Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for standing by.

While the top- and bottom-line numbers for Doximity (DOCS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.3 per share a year ago.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 second quarter ended September 30, 2025. “Our platform continues to grow with new AI tools to save physicians' time,” said Jeff Tangney, co-founder and CEO of Doximity. “In Q2, a record 650,000 prescribers used our workflow tools to better serve their patients, while our AI Scribe and DoxGPT users grew over 50% from the prior quarte.